<DOC>
	<DOCNO>NCT01020370</DOCNO>
	<brief_summary>The primary goal study explore reparative regenerative potential alemtuzumab RRMS patient participate CARE MS I CARE MS II study use conventional non-conventional MRI sequence .</brief_summary>
	<brief_title>Exploratory Study Investigate Reparative Regenerative Potential Alemtuzumab Relapsing-Remitting Multiple Sclerosis Patients Participating CARE MS I MS II Studies</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis , Relapsing-Remitting</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>Participating either CARE MS I CARE MS II study Not participant CARE MS I CARE MS II study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2009</verification_date>
	<keyword>Patients RRMS participate CARE MS I CARE MS II</keyword>
</DOC>